Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen s Revenues Fall, Losses Narrow in Q4

NEW YORK, Feb. 5 (GenomeWeb News) - CuraGen reported falling revenues and smaller losses for the fourth quarter of 2003 today.

 

Revenues for the quarter decreased to $2.5 million from $3.8 million a year ago.

 

CuraGen's R&D expenses decreased to $16.6 million, from $18 million during the same period last year.

 

The company's net loss for the quarter narrowed to $17.5 million, or $.35 per share, from $28.9 million, or $.59 per share, for the year-ago period.

 

As of Dec. 31, CuraGen had cash and investments of $343.6 million.

 

CuraGen said it will continue to focus on clinical studies of its protein, antibody, and small molecule therapeutics this year. Its whole genome sequencing subsidiary, 454 Life Sciences, is planning to bring its first product to market this year.

 

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.